Original Article
Effects of tiotropium bromide combined with lentinan injection on immune function and serum high mobility group proteins and monocyte chemoattractant protein-1 levels in chronic obstructive pulmonary disease patients in stable period
Weilin Ye, Shaoxia Li, Caisheng Wu
Published 2018-11-05
Cite as Int J Respir, 2018, 38(21): 1624-1628. DOI: 10.3760/cma.j.issn.1673-436X.2018.21.005
Abstract
ObjectiveTo explore the effects of tiotropium bromide combined with lentinan injection on immune function and serum high mobility group proteins (HMGB1) and monocyte chemoattractant protein-1 (MCP-1) levels in chronic obstructive pulmonary disease (COPD) patients in stable period.
MethodsA total of 103 patients with stable COPD in our hospital were randomly divided into 2 groups.In the control group, 51 cases were treated with tiotropium bromide, and 52 cases in the observation group were treated with tiotropium bromide combined with lentinan injection.Observe and compare the clinical efficacy and the pulmonary function indexes [forced expiratory volume in one second (FEV1) and FEV1/forced vital capacity (FVC)], immune function indexes [CD3+ , CD4+ , immunoglobulin G (IgG), IgM], and the serum HMGB1, MCP-1 level changes of the two groups before and after the treatment.The incidence of adverse reactionsin the two groups was statistically analyzed.
ResultsThe total effective rate of the observation group was 88.46% (46/52), higher than that of the control group 70.59% (36/51)(χ2=5.067, P<0.05). After 3 months treatment, the FEV1 and FEV1/FVC in the observation group were higher than those in the control group(t=10.706, 7.017, both P<0.05). After 3 months treatment, CD3+ , CD4+ , IgG and IgM in the observation group were higher than those in the control group (t=5.490, 6.114, 19.379, 7.588, all P<0.05). After 3 months treatment, the serum levels of HMGB1 and MCP-1 in the observation group were lower than those in the control group (t=7.461, 16.790, both P<0.05). The incidence of side effects was 11.54% (6/52) in the observation group and 7.84% (4/51) in the control group.There was no significant difference between the two groups (χ2=0.090, P>0.05).
ConclusionsLentinan injection combined with tiotropium bromide can improve the immune function and serum HMGB1 and MCP-1 levels in patients with stable COPD, and promote the recovery of lung function.The curative effect is remarkable, and the safety is high.
Key words:
Chronic obstructive pulmonary disease; Stable period; Tiotropium bromide; Lentinan injection; Immune function
Contributor Information
Weilin Ye
Department of Internal Medicine, the People′s Hospital of Huizhou Zhongkai Hi-tech Zone, Huizhou 516229, China
Shaoxia Li
Caisheng Wu
